Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Dalvance
Dalbavancin is a second-generation lipoglycopeptide antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It exhibits concentration-dependent bactericidal activity by inhibiting bacterial cell wall synthesis. Its long half-life allows for once-weekly dosing.
Treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive organisms.
Outcome:
Increased risk of bleeding
Mechanism:
Dalbavancin may enhance the anticoagulant effects of warfarin.
Outcome:
Reduced efficacy of oral contraceptives
Mechanism:
Unknown
Outcome:
May slightly delay absorption
Mechanism:
Delayed gastric emptying.
Most likely new formulation: extended-release injectable for ABSSSIs and other infections. (Year 2026, 75% confidence)
Based on current usage trends and clinical trial data, dalbavancin is likely to remain a valuable treatment option for ABSSSIs, with a 90% likelihood of continued FDA approval over the next 5 years.
Antibiotic, Glycopeptide
Glycopeptide